Boston Pharmaceuticals

Over the last few days, our team was on-the-ground at American Association for the Study of Liver Diseases (AASLD) #TLM, where we met with leading experts and advocates in the #liverdisease research community. Yesterday, Dr. Mazen Noureddin, MD, MHSc shared our late-breaking Phase 2 results for efimosfermin alfa (formerly BOS-580) in patients with metabolic dysfunction-associated steatohepatitis (#MASH). We are committed in our pursuit to develop new treatment options for patients living with this challenging disease.

Today, we announced positive Phase 2 histology data for efimosfermin alfa (BOS-580), our investigational once-monthly FGF21 analogue, in patients living with #MASH with stage F2/F3 fibrosis. Mazen Noureddin, MD, MHSc will share the topline results with the #liverdisease community in a late-breaking oral presentation on Nov. 19 at AASLD #TLM24. Read our press release to learn more and tune in to our investor webcast on Nov. 21 at 4 p.m. ET: https://lnkd.in/eQyRkWhs ?

We are excited to present new findings in an oral late-breaking presentation for our long-acting, once-monthly FGF21 analogue, efimosfermin alfa (BOS-580) at the American Association for the Study of Liver Diseases (AASLD) annual meeting in San Diego on Nov. 19. These data demonstrate our latest advancements in addressing the unmet needs of patients with metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. #TLM24 ? Read more here: https://lnkd.in/eVGiBWN5

We are thrilled that our Vice President of Medical Affairs, Matthew Bryant, will be speaking at the 8th Annual MASH Drug Development Summit. We look forward to connecting with fellow #liverdisease experts to discuss the ever-evolving treatment landscape for metabolic dysfunction-associated steatohepatitis (#MASH) and #metabolicdiseases. Learn more about this exciting event: https://lnkd.in/eQF_RzUA

We are pleased to announce the appointment of Dr. Margaret Koziel?as Chief Medical Officer of Boston Pharmaceuticals as we advance our promising late-stage candidate BOS-580, an investigational long-acting, once-monthly FGF21 analogue for the treatment of metabolic dysfunction-associated steatohepatitis (#MASH). Throughout her career, Dr. Koziel has been focused on advancing drug development in hepatology and other therapeutic areas from target selection through Phase 4 studies. Her rich experience and deep scientific expertise in liver disease will be instrumental in achieving our next developmental milestones. Read more about this announcement: https://lnkd.in/dauSkeHP

Today we announced new Phase 2a data demonstrating the positive impact of BOS-580, our long-acting FGF21 analogue, on the circulating lipidome and changes in the MASEF score in patients with phenotypic metabolic dysfunction-associated steatohepatitis (#MASH), also known as non-alcoholic steatohepatitis (#NASH). Learn more about these data presented at #EASLCongress here: https://lnkd.in/eeqnQ58J

This week at the #EASLCongress in Milan, we’re sharing our latest Phase 2 data for BOS-580, our long-acting FGF21 analogue being developed for the treatment of metabolic dysfunction-associated steatohepatitis (#MASH), also known as non-alcoholic steatohepatitis (#NASH). Visit us onsite at Booth #O1 to learn more about our research and our pipeline of highly engineered targeted therapies for patients with serious liver diseases.

We are thrilled to announce the appointment of Dr. Elias Zerhouni as the new Chair of the Board of Directors for Boston Pharmaceuticals. Dr. Zerhouni currently serves as Professor Emeritus in Radiology and Biomedical Engineering at Johns Hopkins University, and previously served as a board member and scientific advisor for Boston Pharmaceuticals. We look forward to the level of expertise he will bring to this role that will help drive our ongoing commitment to develop targeted therapies for patients fighting serious liver diseases. Read more about this announcement: https://lnkd.in/eTqY6uKJ

We are seeking a talented, motivated, and goal-oriented individual to join our Program Management team. Learn more and apply at the link below. We can't wait to meet you! #biopharma #drugdevelopment #projectmanagement #boston #kendallsquare #cambridge Celeste DiJohnson

Today we announced additional data from our Phase 2a study of investigational long-acting FGF21 analogue BOS-580 in metabolic dysfunction-associated steatohepatitis (#MASH), also known as non-alcoholic steatohepatitis?(#NASH) at the NASH-TAG Conference. The collective data from our Phase 2 clinical program solidify our commitment to advancing BOS-580 to pivotal clinical trials, with a focus on its once-monthly dosing regimen. Learn more about our data: https://lnkd.in/eZCcAnmW